USPTO serial 76491276
Serial No. 76491276
Reviewed by CopyMark Law Group
Reg. 3068626Status 710
- Filing date
- Status date
- Registration date
- Mar 14, 2006
- Examiner
- EDWARDS, ALICIA COLLINS
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.
Need help with Serial No. 76491276?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Kaushal R. Odedra, Esq.
Ray Thomas, Jr. Wenderoth, Lind & Ponack, L.L.P.1030 15th Street N.W.Suite 400 EastWashington, DC 20005Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Biochemicals, namely, antibodies, monoclonal antibodies, fragments of such antibodies and derivatives of such antibodies for in vitro scientific or research use; cells that manufacture antibody, fragment of antibody or derivatives of antibody for scientific laboratory or medical research; transfected cells that manufactures antibody, fragment of antibody or derivatives of antibody for scientific, laboratory or medical research; host cells for scientific, laboratory or medical research | SECTION 8 - CANCELLED | Jul 1, 1981 |
| 005 | Biochemicals, namely, antibodies, monoclonal antibodies, fragments of such antibodies and derivatives of such antibodies for clinical or medical use; cells that manufacture antibody, fragment of antibody or derivatives of antibody for clinical or medical use; transfected cells that manufactures antibody, fragment of antibody or derivatives of antibody for clinical or medical use; host cells for clinical or medical use; pharmaceuticals, namely, central nervous system depressants; preparations for ophthalmic use, anti-histaminics; cardiotonics; arrhythmia treating agents; diuretics; hypotensors; prophylactic for the treatment of asthma; antitussives and expectorants; stomachics and digestives; antacids; hormones, namely, pituitary hormones for the treatment of infertility; thyroid hormones for the treatment of hyperthyroidism; anabolic hormones for the treatment of a plastic anemia and osteoporosis; corticosteroids for treatment of hypopituitarism, congenital adrenal hyperplasia, rheumatoid arthritis, rheumatic fever, crohn's disease, and chronic active hepatitis; estrogen and progesterone used as combined oral contraceptives; urinary antiseptics; analgesics; anti-itching agents; cataplasms for the treatment of bruises, lumbago and stiff shoulder; pharmaceutical preparations used to treat hair disorders; vitamin preparations; food enriching agents for treating vitamin deficiencies; anti-coagulants; enzyme preparations for control of malabsorption and diarrhea; anti-cancer preparations; anti-sarcoma preparations; antibiotics and their preparations for the treatment of infectious diseases; antituberculotic agents; influenza vaccines; diphtheria vaccines; tetanus vaccines; gas gangrene vaccines, Japanese encephalitis vaccines; in vitro tetrodotoxines for medical use; antiprotozoals for the treatment of trichomoniasis and dermatophytosis; anthelmintics for the treatment of thread worm and toxoplasmaosis; naturally occurring drugs for treating peptic ulcers; charred drugs for treating peptic ulcers; moxa for treating peptic ulcers; veterinary drugs for the treatment of distemper in dogs, distomatosis in dogs, coccidium in chickens, and dysentery in pigs; germination controllers and plant rearing agents, namely, herbicides, fungicides, insecticides, bactericides and rodenticides for domestic and/or agricultural use; antiseptics; drugs for arteriosclerosis; oncostatic drugs for the treatment for cancer; multi enzyme digestants for in vivo use; anti fungal antibiotics for treating trichomoniasis and dermatophytosis; antiparkinsonism drugs; minor tranquilizers; and anti anxiety agents; medicinal preparations for the treatment of the central nervous system, the respiratory tract and the cardiovascular system; vitamins; anti-bacterial preparations; mucolytic preparations; medicinal preparations for the treatment of peptic ulcers; anti-inflammatory preparations; analgesic preparations; cephalosporin; cocarboxylase preparations; gluthathione preparations; preparations for improving the metabolism and the peripheral circulation; plasma substitutes and extra corporeal circulation flow improvement preparations; diuretic and anti-hypertensive preparations; in vitro diagnostic reagents for medical use, in vitro extra corporeal diagnostic reagents for medical use, in vitro X-ray contrast agents for medical use, in vitro diagnostic media; pharmaceutical preparations for the treatment of insomnia and other sleep related diseases | SECTION 8 - CANCELLED | Jul 1, 1981 |
| 040 | Custom manufacturing of antibody, fragment of antibody or derivatives of antibody; custom manufacturing of cells that manufactures antibody, fragment of antibody or derivatives of antibody; custom manufacturing of transfected cells that manufactures antibody, fragment of antibody or derivatives of antibody; custom manufacturing of host cells | SECTION 8 - CANCELLED | Jul 1, 1981 |
| 042 | Contract development for antibody, fragment of antibody or derivatives of antibody; contract development for cells that manufactures antibody, fragment of antibody or derivatives of antibody; contract development for transfected cells that manufactures antibody, fragment of antibody or derivatives of antibody; contract development for host cells | SECTION 8 - CANCELLED | Jul 1, 1981 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Kyowa Hakko Kogyo Co., Ltd.
- Other trademarks owned by Kyowa Hakko Kogyo Co., Ltd.
- Other trademarks owned by Kyowa Hakko Kogyo Co., Ltd.
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 040
- Other trademarks in Class 042
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 19, 2012 | C8.. | CANCELLED SEC. 8 (6-YR) | — |
| Jan 13, 2010 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Mar 14, 2006 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jan 31, 2006 | REGV | LAW OFFICE REGISTRATION REVIEW COMPLETED | — |
| Jan 20, 2006 | ALIE | ASSIGNED TO LIE | — |
| Jan 19, 2006 | CNPR | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | — |
| Dec 7, 2005 | SUPC | STATEMENT OF USE PROCESSING COMPLETE | — |
| Nov 10, 2005 | IUAF | USE AMENDMENT FILED | — |
| Nov 10, 2005 | PAPER RECEIVED | — | |
| May 10, 2005 | NOAM | NOA MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Mar 2, 2005 | ETOP | EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED | — |
| Sep 2, 2004 | ETOF | EXTENSION OF TIME TO OPPOSE RECEIVED | — |
| Aug 3, 2004 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jul 14, 2004 | NPUB | NOTICE OF PUBLICATION | — |
| May 18, 2004 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| May 3, 2004 | CNEA | EXAMINERS AMENDMENT MAILED | — |
| Feb 10, 2004 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 10, 2004 | PAPER RECEIVED | — | |
| Aug 12, 2003 | CNRT | NON-FINAL ACTION MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 8, 2003 | DOCK | ASSIGNED TO EXAMINER | — |
| Mar 20, 2003 | PAPER RECEIVED | — |